Validation using Nucleic Acid Testing (NAT) on Blood Donor Samples Non-Reactive to Transfusion-Transmissible Viruses by Immunoassay (EIA/ChLIA)

Authors

  • Rhoda Yu Research Institute for Tropical Medicine
  • Iza Mae Chamen Research Institute for Tropical Medicine http://orcid.org/0000-0002-8088-0292
  • Kenneth Aristotle Punzalan Research Institute for Tropical Medicine http://orcid.org/0000-0002-0564-2331
  • Benjamin De Vera III Research Institute for Tropical Medicine
  • Elizabeth Arcellana-Nuqui The Medical City

Keywords:

blood transfusions, human immunodeficiency virus, hepatitis, transfusion transmissible infections, nucleic acid test

Abstract

Transfusion-transmissible infections (HIV, HBV and HCV) remain a threat to public health specifically in assuring safe transfusion practices. This study aims to determine the ability of a blood service facility to accurately detect HIV, Hepatitis B and C and assess the need to include nucleic acid testing as part of the routine screening algorithm. Of the 3,233 samples from participants with screened sero-negative blood units, testing for HIV and Hepatitis C showed no discrepancies with EIA and NAT in all samples. Testing for Hepatitis B showed 12 (4.00%) samples which are reactive in both EIA and NAT, 3 (0.09%) samples were reactive with EIA only and 48 (1.48%) were detected for the presence of Hepatitis B Virus via NAT.

Downloads

Download data is not yet available.

Author Biography

Kenneth Aristotle Punzalan, Research Institute for Tropical Medicine

Medical Specialist IV; Head-Department of Virology

References

1. Lam HY, Belizario VY, Juban NR, Alejandria MM, Castillo-Carandang N, Arcellana-Nuqui E, Mirasol MA, et al. Assessing the residual risk for transfusion-transmitted infections in the Philippine blood supply. Yale J Biol Med. 2014;87(3):299–306. PMCID: PMC4144284.

2. Department of Health. Negative validation study for transfusion-transmissible infections in selected government and Philippine Red Cross Blood Service Facilities in the country. Manila, Philippines: Department Circular No. 2014-0032.

3. Scheiblauer H, El-Nageh M, Diaz S, Nick S, Zeichhardt H, Grunert HP, et al. Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes. Vox Sanguinis. 2009;98(3p2):403-14. https://doi.org/10.1111/j.1423-0410.2009.01272.x.

4. Sharma SK, Saini N, Chwla Y. Hepatitis B virus: inactive carriers. Virol J. 2005;2:82. https://doi.org/10.1186/1743-422X-2-82.

5. Wong SN, Ong JP, Labio ME, Cabahug OT, Daez ML, Valdellon EV, ey al. Hepatitis B infection among adults in the Philippines: a national seroprevalence study. World J Hepatol. 2013;5(4):214-9. https://doi.org/10.4254/wjh.v5.i4.214. PMID: 23671726. PMCID: PMC3648653.

6. Duncan R, Kourout M, Grigorenko E, Fisher C, Dong M. Advances in multiplex nucleic acid diagnostics for blood-borne pathogens: promises and pitfalls. Expert Rev Mol Diagn. 2016;16(1). https://doi.org/10.1586/14737159.2016.1112272.

7. Pourazar A, Salehi M, Jafarzadeh A, Arababadi MK, Oreizi F, Shariatinezhad K. Detection of HBV DNA in HBsAg negative normal blood donors. IJI. 2005;2(3):172–6.

8. Chigurapati P, Srinivasa Murthy K, Automated nucleic acid amplification testing in blood banks: an additional layer of blood safety. Asian J Transfus Sci. 2015;9(1): 9-11. https://doi.org/10.4103/0973-6247.150938. PMCID: PMC4339944.

9. Kumar H, Gupta PK, Jaiprakash M. The role of anti-HBc IgM in screening of blood donors. Med J Armed Forces India. 2007;63(4):350-2. https://doi.org/ 10.1016/S0377-1237(07)80013-X.

Published

2016-12-19

How to Cite

Yu, R., Chamen, I. M., Punzalan, K. A., De Vera III, B., & Arcellana-Nuqui, E. (2016). Validation using Nucleic Acid Testing (NAT) on Blood Donor Samples Non-Reactive to Transfusion-Transmissible Viruses by Immunoassay (EIA/ChLIA). PJP, 2(1), 39. Retrieved from https://philippinejournalofpathology.org/index.php/PJP/article/view/49

Issue

Section

Brief Communications